Literature DB >> 16926548

Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.

Keiko Arataki1, Hiromitsu Kumada, Kiyomi Toyota, Waka Ohishi, Shoichi Takahashi, Susumu Tazuma, Kazuaki Chayama.   

Abstract

OBJECTIVE: Ribavirin and interferon combination therapy is more effective than interferon monotherapy in patients with chronic hepatitis C virus (HCV) infection. To test the hypothesis that ribavirin induces nucleotide substitutions in the viral genome and reduces viral load by forcing it into error catastrophe in the combination therapy, we investigated the molecular evolution of HCV quasispecies in 3 patients who received combination therapy and 2 patients who received interferon monotherapy.
METHODS: The quasispecies were analyzed before and after therapy by sequencing at least 8 clones in five regions of the HCV genome; 5' untranslated region, EI, E2, NS5A and NS5B.
RESULTS: Marked genetic drift was observed in the NS5A and NS5B regions in patients treated with combination therapy. However, genetic distances between clones obtained after therapy were closer than those obtained before therapy.
CONCLUSION: Our results suggest that the combination therapy modified HCV quasispecies, but that this did not reflect the induction of error catastrophe by ribavirin. Modification of quasispecies by this therapy requires further investigation in a larger number of patients to elucidate the possible mechanism of viral resistance against the combination therapy. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926548     DOI: 10.1159/000095155

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  5 in total

1.  Analysis of ribavirin mutagenicity in human hepatitis C virus infection.

Authors:  Stéphane Chevaliez; Rozenn Brillet; Ester Lázaro; Christophe Hézode; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

2.  Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.

Authors:  Aaditya Bhatt; K R Gurukumar; Amartya Basu; Maulik R Patel; Neerja Kaushik-Basu; Tanaji T Talele
Journal:  Eur J Med Chem       Date:  2011-08-26       Impact factor: 6.514

3.  Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.

Authors:  Tanaji T Talele; Payal Arora; Shridhar S Kulkarni; Maulik R Patel; Satyakam Singh; Maksim Chudayeu; Neerja Kaushik-Basu
Journal:  Bioorg Med Chem       Date:  2010-05-15       Impact factor: 3.641

4.  Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.

Authors:  Neerja Kaushik-Basu; Alain Bopda-Waffo; Tanaji T Talele; Amartya Basu; Paulo R R Costa; Alcides J M da Silva; Stefan G Sarafianos; François Noël
Journal:  Nucleic Acids Res       Date:  2008-01-18       Impact factor: 16.971

5.  Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Authors:  Nathan A Cannon; Maureen J Donlin; Xiaofeng Fan; Rajeev Aurora; John E Tavis
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.